IN2012DN03362A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03362A
IN2012DN03362A IN3362DEN2012A IN2012DN03362A IN 2012DN03362 A IN2012DN03362 A IN 2012DN03362A IN 3362DEN2012 A IN3362DEN2012 A IN 3362DEN2012A IN 2012DN03362 A IN2012DN03362 A IN 2012DN03362A
Authority
IN
India
Prior art keywords
psoriasis
immune
treatment
antibodies against
humanized antibodies
Prior art date
Application number
Inventor
Roland Beckmann
Caroline Johnson-Leger
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03362(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of IN2012DN03362A publication Critical patent/IN2012DN03362A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention relates to humanized antibodies against human IL-22RA and to their use in the treatment of psoriasis and other immune-mediated diseases such as psoriatic arthritis and atopic dermatitis.
IN3362DEN2012 2009-11-19 2010-11-12 IN2012DN03362A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (1)

Publication Number Publication Date
IN2012DN03362A true IN2012DN03362A (en) 2015-10-23

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3362DEN2012 IN2012DN03362A (en) 2009-11-19 2010-11-12

Country Status (19)

Country Link
US (1) US8545844B2 (en)
EP (1) EP2512511B1 (en)
JP (1) JP5818804B2 (en)
KR (1) KR20120098783A (en)
CN (1) CN102665759B (en)
AU (1) AU2010321047B2 (en)
BR (1) BR112012012003A2 (en)
CA (1) CA2778864C (en)
EA (1) EA021356B1 (en)
EC (1) ECSP12011980A (en)
ES (1) ES2531996T3 (en)
IL (1) IL219740A0 (en)
IN (1) IN2012DN03362A (en)
MX (1) MX2012005791A (en)
NZ (1) NZ599438A (en)
PE (1) PE20121560A1 (en)
UA (1) UA105405C2 (en)
WO (1) WO2011061119A1 (en)
ZA (1) ZA201202793B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004770A (en) * 2004-10-22 2007-11-22 Zymogenetics Inc Anti-il-22ra antibodies and binding partners and methods of using in inflammation.
PT2686347T (en) 2011-03-16 2018-07-05 Argenx Bvba Antibodies to cd70
CN107318267B (en) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 Compositions and methods for treating complement-associated disorders
BR112016025312A2 (en) * 2014-05-01 2017-10-17 Genentech Inc antibody variants, anti-d-factor antibody, pharmaceutical formulation, dispensing device, use of the formulation and a composition, composition and method of treating a disorder
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CN108472382A (en) * 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 Anti- factor D antibody variants conjugate and application thereof
JP2018534930A (en) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド Anti-factor D antibodies and conjugates
EP3431494B1 (en) 2016-03-18 2024-05-01 Staidson(Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor mutant
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
TWI714854B (en) * 2017-05-24 2021-01-01 財團法人生物技術開發中心 Humanized antibodies against globo h and uses thereof in cancer treatments
JP7245793B2 (en) 2017-06-30 2023-03-24 ザイムワークス ビーシー インコーポレイテッド Stabilized chimeric Fab
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2023232789A1 (en) * 2022-06-03 2023-12-07 Leo Pharma A/S Liquid formulation of il-22r antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
MX2007004770A (en) 2004-10-22 2007-11-22 Zymogenetics Inc Anti-il-22ra antibodies and binding partners and methods of using in inflammation.
MX2007011407A (en) 2005-03-25 2007-11-13 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function.
JP2009518314A (en) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling comprising antibodies that bind IL-22 and antibodies that bind IL-22R

Also Published As

Publication number Publication date
CA2778864C (en) 2017-06-27
KR20120098783A (en) 2012-09-05
JP5818804B2 (en) 2015-11-18
US8545844B2 (en) 2013-10-01
ZA201202793B (en) 2013-06-26
UA105405C2 (en) 2014-05-12
MX2012005791A (en) 2012-07-03
EA201290360A1 (en) 2012-11-30
CN102665759A (en) 2012-09-12
CA2778864A1 (en) 2011-05-26
EA021356B1 (en) 2015-05-29
US20120230990A1 (en) 2012-09-13
AU2010321047A1 (en) 2012-05-24
PE20121560A1 (en) 2012-12-05
EP2512511A1 (en) 2012-10-24
ECSP12011980A (en) 2012-07-31
ES2531996T3 (en) 2015-03-23
NZ599438A (en) 2013-12-20
EP2512511B1 (en) 2015-01-07
JP2013511267A (en) 2013-04-04
IL219740A0 (en) 2012-07-31
CN102665759B (en) 2015-09-30
WO2011061119A1 (en) 2011-05-26
AU2010321047B2 (en) 2016-06-09
BR112012012003A2 (en) 2016-11-29

Similar Documents

Publication Publication Date Title
IN2012DN03362A (en)
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2582722A4 (en) Anti-gd2 antibodies
MX2018009524A (en) Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use.
UA115887C2 (en) Amino-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
MX2012011768A (en) Antibodies that bind human cd27 and uses thereof.
GB201109238D0 (en) Antibodies
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
UA106586C2 (en) Anti-cd79b antibodies and imunokonugate and methods for their use
NZ599737A (en) Il-17a antagonists
IN2015DN02826A (en)
MX354095B (en) Human oncostatin m antibodies and methods of use.
MX353476B (en) Anti-cxcl13 antibodies and methods of using the same.
MX2013001267A (en) Antibodies to il-1beta and il-18, for treatment of disease.
MX2015008534A (en) ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF.
MX2013002121A (en) Substituted quinoline-3-carboxamides as kcnq2/3 modulators.
EA201891594A1 (en) ANTIBODIES TO IL-17C
UA110051C2 (en) Normal;heading 1;heading 2;heading 3;ANTIBODY THAT BINDS TGF-ALPHA AND EPIREGULIN
WO2011019636A3 (en) Methods and compositions for the treatment of cancers and pathogenic infections
EP2569018A4 (en) Humanized ttc and methods of use thereof
WO2012084993A3 (en) Biologically active oligonucleotides capable of modulating the immune system i
UA112965C2 (en) HUMANIZED ANTIBODY TO IL-25
SG10201909377XA (en) Antibodies that bind human cd27 and uses thereof
NZ757754A (en) Antibodies that bind csf1r